Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Targeting CD10 on B-Cell Leukemia Using the Universal CAR T-Cell Platform (UniCAR)

N. Mitwasi, C. Arndt, LR. Loureiro, A. Kegler, F. Fasslrinner, N. Berndt, R. Bergmann, V. Hořejší, C. Rössig, M. Bachmann, A. Feldmann

. 2022 ; 23 (9) : . [pub] 20220428

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22018695

Chimeric antigen receptor (CAR)-expressing T-cells are without a doubt a breakthrough therapy for hematological malignancies. Despite their success, clinical experience has revealed several challenges, which include relapse after targeting single antigens such as CD19 in the case of B-cell acute lymphoblastic leukemia (B-ALL), and the occurrence of side effects that could be severe in some cases. Therefore, it became clear that improved safety approaches, and targeting multiple antigens, should be considered to further improve CAR T-cell therapy for B-ALL. In this paper, we address both issues by investigating the use of CD10 as a therapeutic target for B-ALL with our switchable UniCAR system. The UniCAR platform is a modular platform that depends on the presence of two elements to function. These include UniCAR T-cells and the target modules (TMs), which cross-link the T-cells to their respective targets on tumor cells. The TMs function as keys that control the switchability of UniCAR T-cells. Here, we demonstrate that UniCAR T-cells, armed with anti-CD10 TM, can efficiently kill B-ALL cell lines, as well as patient-derived B-ALL blasts, thereby highlighting the exciting possibility for using CD10 as an emerging therapeutic target for B-cell malignancies.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22018695
003      
CZ-PrNML
005      
20220804134955.0
007      
ta
008      
220720s2022 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/ijms23094920 $2 doi
035    __
$a (PubMed)35563312
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Mitwasi, Nicola $u Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Bautzner Landstraße 400, D-01328 Dresden, Germany
245    10
$a Targeting CD10 on B-Cell Leukemia Using the Universal CAR T-Cell Platform (UniCAR) / $c N. Mitwasi, C. Arndt, LR. Loureiro, A. Kegler, F. Fasslrinner, N. Berndt, R. Bergmann, V. Hořejší, C. Rössig, M. Bachmann, A. Feldmann
520    9_
$a Chimeric antigen receptor (CAR)-expressing T-cells are without a doubt a breakthrough therapy for hematological malignancies. Despite their success, clinical experience has revealed several challenges, which include relapse after targeting single antigens such as CD19 in the case of B-cell acute lymphoblastic leukemia (B-ALL), and the occurrence of side effects that could be severe in some cases. Therefore, it became clear that improved safety approaches, and targeting multiple antigens, should be considered to further improve CAR T-cell therapy for B-ALL. In this paper, we address both issues by investigating the use of CD10 as a therapeutic target for B-ALL with our switchable UniCAR system. The UniCAR platform is a modular platform that depends on the presence of two elements to function. These include UniCAR T-cells and the target modules (TMs), which cross-link the T-cells to their respective targets on tumor cells. The TMs function as keys that control the switchability of UniCAR T-cells. Here, we demonstrate that UniCAR T-cells, armed with anti-CD10 TM, can efficiently kill B-ALL cell lines, as well as patient-derived B-ALL blasts, thereby highlighting the exciting possibility for using CD10 as an emerging therapeutic target for B-cell malignancies.
650    _2
$a antigeny CD19 $x metabolismus $7 D018941
650    _2
$a lidé $7 D006801
650    _2
$a imunoterapie adoptivní $7 D016219
650    12
$a leukemie B-buněčná $x metabolismus $x terapie $7 D015448
650    12
$a chronická lymfatická leukemie $x metabolismus $x terapie $7 D015451
650    12
$a neprilysin $x terapeutické užití $7 D015260
650    _2
$a receptory antigenů T-buněk $x metabolismus $7 D011948
650    _2
$a T-lymfocyty $7 D013601
655    _2
$a časopisecké články $7 D016428
700    1_
$a Arndt, Claudia $u Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Bautzner Landstraße 400, D-01328 Dresden, Germany $u Mildred Scheel Early Career Center, Faculty of Medicine Carl Gustav Carus, TU Dresden, D-01307 Dresden, Germany $1 https://orcid.org/0000000212855052
700    1_
$a Loureiro, Liliana R $u Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Bautzner Landstraße 400, D-01328 Dresden, Germany
700    1_
$a Kegler, Alexandra $u Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Bautzner Landstraße 400, D-01328 Dresden, Germany
700    1_
$a Fasslrinner, Frederick $u Mildred Scheel Early Career Center, Faculty of Medicine Carl Gustav Carus, TU Dresden, D-01307 Dresden, Germany $u Medical Clinic and Polyclinic I, University Hospital Carl Gustav Carus, TU Dresden, D-01307 Dresden, Germany
700    1_
$a Berndt, Nicole $u Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Bautzner Landstraße 400, D-01328 Dresden, Germany
700    1_
$a Bergmann, Ralf $u Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Bautzner Landstraße 400, D-01328 Dresden, Germany $u Department of Biophysics and Radiation Biology, Semmelweis University, H-1094 Budapest, Hungary $1 https://orcid.org/0000000287334286
700    1_
$a Hořejší, Vaclav $u Institute of Molecular Genetics of the Academy of Sciences of the Czech Republic, 142 20 Prague, Czech Republic
700    1_
$a Rössig, Claudia $u Department of Pediatric Hematology and Oncology, University Children's Hospital Münster, 48149 Münster, Germany
700    1_
$a Bachmann, Michael $u Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Bautzner Landstraße 400, D-01328 Dresden, Germany $u National Center for Tumor Diseases (NCT), D-01307 Dresden, Germany $u German Cancer Consortium (DKTK), Partner Site Dresden and German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany $u Tumor Immunology, University Cancer Center (UCC), University Hospital Carl Gustav Carus, TU Dresden, D-01307 Dresden, Germany $1 https://orcid.org/0000000280295755
700    1_
$a Feldmann, Anja $u Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Bautzner Landstraße 400, D-01328 Dresden, Germany
773    0_
$w MED00176142 $t International journal of molecular sciences $x 1422-0067 $g Roč. 23, č. 9 (2022)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35563312 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804134949 $b ABA008
999    __
$a ok $b bmc $g 1822357 $s 1169938
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 23 $c 9 $e 20220428 $i 1422-0067 $m International journal of molecular sciences $n Int J Mol Sci $x MED00176142
LZP    __
$a Pubmed-20220720
Zpět

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace